[
  {
    "ts": "2025-12-04T12:39:00+00:00",
    "headline": "How Strong Is AbbVie's Immunology Franchise After Humira's LOE?",
    "summary": "ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.",
    "url": "https://finance.yahoo.com/news/strong-abbvies-immunology-franchise-humiras-123900413.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2e332b71-3833-3572-a4df-6abc427e0a3e",
      "content": {
        "id": "2e332b71-3833-3572-a4df-6abc427e0a3e",
        "contentType": "STORY",
        "title": "How Strong Is AbbVie's Immunology Franchise After Humira's LOE?",
        "description": "",
        "summary": "ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.",
        "pubDate": "2025-12-04T12:39:00Z",
        "displayTime": "2025-12-04T12:39:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/strong-abbvies-immunology-franchise-humiras-123900413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/strong-abbvies-immunology-franchise-humiras-123900413.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T14:27:00+00:00",
    "headline": "3 Large Drug Stocks to Watch as the Industry Shows Some Recovery",
    "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.",
    "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "18569e85-7832-39f7-8e4b-10938849c2b4",
      "content": {
        "id": "18569e85-7832-39f7-8e4b-10938849c2b4",
        "contentType": "STORY",
        "title": "3 Large Drug Stocks to Watch as the Industry Shows Some Recovery",
        "description": "",
        "summary": "In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.",
        "pubDate": "2025-12-04T14:27:00Z",
        "displayTime": "2025-12-04T14:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Z6CaNjdpI8OLeo5.Ul_eA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o6kyOwY40meLORq99yf8XA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-large-drug-stocks-watch-142700725.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T16:44:17+00:00",
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,075.47 as of November 28th. LLY’s trailing and forward P/E were 52.69 and 33.90, respectively according to Yahoo Finance. Eli Lilly […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-164417555.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8bfa5050-e0b9-39ed-a333-c72a85a9dedc",
      "content": {
        "id": "8bfa5050-e0b9-39ed-a333-c72a85a9dedc",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Eli Lilly and Company on Pebble Bites’s Substack by Christina Gan. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company’s share was trading at $1,075.47 as of November 28th. LLY’s trailing and forward P/E were 52.69 and 33.90, respectively according to Yahoo Finance. Eli Lilly […]",
        "pubDate": "2025-12-04T16:44:17Z",
        "displayTime": "2025-12-04T16:44:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c",
          "originalWidth": 768,
          "originalHeight": 430,
          "caption": "Was Jim Cramer Right About Eli Lilly and Company (LLY)?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DFQyzS.MgxX7FGup4wuuQQ--~B/aD00MzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 768,
              "height": 430,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Lop4Pg7FGZ0GE4bKJLODDA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/a9fb68fd7057548f7ce119cac6a87e1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-164417555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-bull-164417555.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T18:59:14+00:00",
    "headline": "Avidity Biosciences, Inc. (RNA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.’s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The […]",
    "url": "https://finance.yahoo.com/news/avidity-biosciences-inc-rna-bull-185914399.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "33c6ac86-90f2-383a-bb3f-633401040ceb",
      "content": {
        "id": "33c6ac86-90f2-383a-bb3f-633401040ceb",
        "contentType": "STORY",
        "title": "Avidity Biosciences, Inc. (RNA): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Avidity Biosciences, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on RNA. Avidity Biosciences, Inc.’s share was trading at $71.54 as of December 2nd. Novartis is acquiring Avidity RNA, a pre-Phase 3 biotech company, in a straightforward deal with no overlap between the two businesses. The […]",
        "pubDate": "2025-12-04T18:59:14Z",
        "displayTime": "2025-12-04T18:59:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "microscope, health",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/jlSXk2cfZ4LwsZmEizTJog--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GFu55GtTL41F2Sa4eWKtSw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b5dad9919dcf999502a6a0d2fc5a1f43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/avidity-biosciences-inc-rna-bull-185914399.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/avidity-biosciences-inc-rna-bull-185914399.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RNA"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T18:53:34+00:00",
    "headline": "Danaher Stock Earns Relative Strength Rating Upgrade",
    "summary": "Danaher stock had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.    When To Sell Stocks To Lock In Profits And Minimize Losses  IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score.",
    "url": "https://www.investors.com/news/danaher-stock-earns-relative-strength-rating-upgrade/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "342505b8-1bb8-364c-a3d8-827032638258",
      "content": {
        "id": "342505b8-1bb8-364c-a3d8-827032638258",
        "contentType": "STORY",
        "title": "Danaher Stock Earns Relative Strength Rating Upgrade",
        "description": "",
        "summary": "Danaher stock had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday — a welcome improvement, but still shy of the 80 or higher score you prefer to see.    When To Sell Stocks To Lock In Profits And Minimize Losses  IBD's unique rating tracks market leadership with a 1 (worst) to 99 (best) score.",
        "pubDate": "2025-12-04T18:53:34Z",
        "displayTime": "2025-12-04T18:53:34Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/342505b8-1bb8-364c-a3d8-827032638258/danaher-stock-earns-relative.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/c0cfcba9d362bfd8713ce3997b701f20",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ktTehIKUBT59XHtifmIPRA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c0cfcba9d362bfd8713ce3997b701f20.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aCru6l35vPKCAKPOaklVmQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/c0cfcba9d362bfd8713ce3997b701f20.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/danaher-stock-earns-relative-strength-rating-upgrade/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DHR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T18:50:53+00:00",
    "headline": "Denmark's $600 Billion Economy Just Got a Boost--Thanks to One Drugmaker",
    "summary": "Novo Nordisk's weight on GDP, jobs, and exports is reshaping Denmark's growth story despite layoffs and tariff headwinds.",
    "url": "https://finance.yahoo.com/news/denmarks-600-billion-economy-just-185053471.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "d15997e2-0628-3ec4-8596-fa6d0d13f105",
      "content": {
        "id": "d15997e2-0628-3ec4-8596-fa6d0d13f105",
        "contentType": "STORY",
        "title": "Denmark's $600 Billion Economy Just Got a Boost--Thanks to One Drugmaker",
        "description": "",
        "summary": "Novo Nordisk's weight on GDP, jobs, and exports is reshaping Denmark's growth story despite layoffs and tariff headwinds.",
        "pubDate": "2025-12-04T18:50:53Z",
        "displayTime": "2025-12-04T18:50:53Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/denmarks-600-billion-economy-just-185053471.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/denmarks-600-billion-economy-just-185053471.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-04T16:42:00+00:00",
    "headline": "LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock",
    "summary": "Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.",
    "url": "https://finance.yahoo.com/news/lly-trading-above-50-200-164200020.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e871e9de-f4fd-32bc-b57d-9be9782c585f",
      "content": {
        "id": "e871e9de-f4fd-32bc-b57d-9be9782c585f",
        "contentType": "STORY",
        "title": "LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock",
        "description": "",
        "summary": "Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.",
        "pubDate": "2025-12-04T16:42:00Z",
        "displayTime": "2025-12-04T16:42:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lly-trading-above-50-200-164200020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lly-trading-above-50-200-164200020.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]